Healthy living for all, together we uphold, and start a new chapter! September is the National Healthy Lifestyle Promotion Month. We focus on breast cancer, a significant disease threatening women's health, and have specially invited authoritative experts in the field of breast cancer from China to discuss the scientific prevention and treatment of breast cancer and the importance of a healthy lifestyle. The experts unanimously emphasize that facing the disease scientifically, actively preventing it, and treating it precisely are the keys to overcoming breast cancer. Let us join hands with a scientific attitude and firm belief to protect the beauty and dignity of life, and promote breast cancer prevention and treatment to new heights, contributing to the great goal of a Healthy China! We hope that through the experts' interpretations, we can not only enhance the public's understanding of breast cancer but also encourage patients and their families to actively participate in screening and advocate a healthy lifestyle, jointly promoting the development of breast cancer treatment towards more individualized and precise directions. Let us work together to light the way for breast cancer patients and create a healthy and bright future!

Histone deacetylases (HDACs) are overexpressed in various tumors and are closely related to tumor progression and drug resistance. In hormone receptor-positive (HR+) breast cancer, HDAC overexpression leads to resistance to endocrine therapy and CDK4/6 inhibitors. The targeted application of HDAC inhibitors (HDACi) can effectively block this process, bringing better prognosis to patients. Entinostat, introduced in 1997, has undergone over two decades of meticulous research and development, and has become the first HDACi to achieve overall survival (OS) benefits in patients with HR+ metastatic breast cancer in China, offering new treatment options for Chinese patients. Professor Yehui Shi from the Tianjin Medical University Cancer Hospital will review the milestone events in the clinical exploration and application of HDACi entinostat in breast cancer, allowing the light of epigenetic regulation to shine on patients with HR+ metastatic breast cancer.

Breast cancer is one of the most common malignant tumors in women and is often referred to as the "pink killer," posing a serious threat to women's health. The World Health Organization has designated October as "World Breast Cancer Awareness Month" (also known as Pink Ribbon Month) to raise women's awareness of breast cancer prevention. The motto of the Pink Ribbon Breast Cancer Prevention Campaign is "early prevention, early detection, and early treatment." To enhance women's awareness of breast cancer prevention and treatment, Edding Group Company Limited, in collaboration with "Oncology Frontier," has specially invited leading domestic experts in the field of breast cancer. Combining clinical practice and research results, they have in-depth discussions on the importance of early screening, precise treatment, and healthy lifestyles for breast cancer.

Breast cancer is one of the most common malignant tumors in women and is often referred to as the "pink killer," posing a serious threat to women's health. The World Health Organization has designated October as "World Breast Cancer Awareness Month" (also known as Pink Ribbon Month) to raise women's awareness of breast cancer prevention. The motto of the Pink Ribbon Breast Cancer Prevention Campaign is "early prevention, early detection, and early treatment." To enhance women's awareness of breast cancer prevention and treatment, Edding Group Company Limited, in collaboration with "Oncology Frontier," has specially invited leading domestic experts in the field of breast cancer. Combining clinical practice and research results, they have in-depth discussions on the importance of early screening, precise treatment, and healthy lifestyles for breast cancer.

Editor's Note: At the 2024 SABCS conference, Professor Charles Geyer from the University of Pittsburgh, USA, presented the latest progress of the NSABP B-59/GBG-96-GeparDouze study. The study investigated whether the…

Editor's Note: At the 2024 SABCS conference, Professor Janice Tsang from the Li Ka Shing Faculty of Medicine, The University of Hong Kong, presented on "Early Breast Cancer Updates" during…

Editor's Note: In the journey of cancer treatment, chemotherapy acts as a double-edged sword, bringing hope for survival to patients while also accompanying a series of adverse reactions, among which…

Editor's Note: On the international stage of breast cancer research, Professor Michael Gnant from the Comprehensive Cancer Center of the Medical University of Vienna, Austria, has become a highly respected…

A pivotal study published on April 23, 2024, in the Journal of Clinical Oncology explored the efficacy of Datopotamab Deruxtecan (Dato-DXd) in advanced HR+/HER2– and triple-negative breast cancer (TNBC). Led…